AI resources like Chat GPT get better and better at scouring the internet.
Can it find molecular diagnostics funding events? In the last month or two, I had noticed the SPAC for Freenome; the Series B for Mercy BioAnalytics; the Series B for Precede Biosciences.
I asked Chat GPT if it could find those and any others from November 1 to January 13.
###
[Direct AI result. See output with links here.]
###
Molecular Diagnostics & Testing -
Funding and SPAC Events (Nov 2025–Jan 2026)
⭐ Major Events
• Freenome — SPAC / Public Listing (~$330M)
Cancer blood test developer Freenome announced plans to go public via a SPAC transaction that is expected to raise approximately $330 million to support development and commercialization of its blood-based cancer detection tests. The deal includes ~$240M in committed equity from Perceptive Advisors, RA Capital, Bain Capital Life Sciences, and others, plus ~$90M in SPAC trust funds.
• Precede Biosciences — $83.5M Total Financing (Series B + Credit Facility)
Boston-based Precede Biosciences secured $83.5 million in total financing, comprised of $63.5 M Series B equity and a $20 M strategic non-dilutive credit facility to scale its next-generation precision diagnostics platform focused on genome-wide transcriptional biology from blood.
• Mercy BioAnalytics — ~$59M Series B Financing
Mercy BioAnalytics closed a $59 million Series B to advance its extracellular vesicle-based liquid biopsy and early cancer detection programs (with primary focus on ovarian cancer screening and expansion to other indications). The round was co-led by Novalis and Sozo Ventures with participation from strategic investors like Hologic, Bruker Scientific, and Labcorp.
💡 Additional Molecular Diagnostics / Testing Funding Rounds
• KIFFIK Biomedical — Series A (Oversubscribed)
KIFFIK Biomedical closed an oversubscribed Series A financing round to advance its real-time molecular diagnostics platform.
• Adaptive Bio — Planned Series A (~$15M)
Adaptive Bio announced plans to raise around $15 million in Series A financing for its clinical sequencing operations, aiming to expand clinical genomic sequencing and molecular testing services.
• Elephas — Series B2 (~$40M)
Elephas completed a $40 million Series B2 focused on imaging-based diagnostics with implications for functional oncology and precision diagnostics.
• Hermes Biosciences — Seed Funding (~$6M)
Hermes Biosciences raised about $6 million in seed funding for developing extracellular vesicle tools and technologies relevant to precision medicine and diagnostics.
• CrisprBits — Pre-Series A (~$3M)
Indian CRISPR diagnostics startup CrisprBits raised roughly $3 million Pre-Series A to expand its CRISPR-based molecular diagnostics platform.
📊 Summary Table
| Company | Event / Round | Amount | Focus |
|---|---|---|---|
| Freenome | SPAC / Public Listing | ~$330M | Multi-cancer blood-based cancer detection tech |
| Precede Biosciences | Series B + Credit | $83.5M | Precision liquid biopsy and transcriptional diagnostics |
| Mercy BioAnalytics | Series B | $59M | Early cancer detection (extracellular vesicles) |
| KIFFIK Biomedical | Series A | Oversubscribed | Real-time molecular diagnostics |
| Adaptive Bio | Planned Series A | ~$15M | Clinical sequencing & molecular testing expansion |
| Elephas | Series B2 | ~$40M | Functional oncology diagnostics |
| Hermes Biosciences | Seed | ~$6M | Extracellular vesicle technologies |
| CrisprBits | Pre-Series A | ~$3M | CRISPR-based molecular diagnostics |
